Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?

DURCAN, EMRE; Osar Siva, Zeynep; Sahin, Serdar; Damci, Taner; Ilkova, Hasan; Haliloglu, Ozlem; Polat Korkmaz, Ozge; Yumuk, Volkan Demirhan; Rekalı Sahin, Humeyra

doi:10.3906/sag-2008-37

Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?

Serdar ŞAHİN, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Özlem HALİLOĞLU, (Taksim Eğitim ve Araştırma Hastanesi, İç Hastalıkları Anabilim Dalı, İstanbul, Türkiye)

Özge POLAT KORKMAZ, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Emre DURCAN, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Hümeyra REKALI ŞAHİN, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Volkan Demirhan YUMUK, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Taner DAMCI, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Hasan İLKOVA, (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Zeynep OŞAR SİVA (İstanbul Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı-Cerrahpaşa, İstanbul, Türkiye)

Turkish Journal of Medical Sciences

2 0

Yıl: 2021 Cilt: 51 Sayı: 2 Sayfa Aralığı: 735 - 742 Metin Dili: İngilizce DOI: 10.3906/sag-2008-37 İndeks Tarihi: 24-01-2022

Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?

Öz:

Background/aim: To evaluate the impact of treatment with sodium-glucose co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients with Type 2 diabetes mellitus (T2DM). Materials and methods: Ninety-seven patients with type 2 diabetes admitted to tertiary care hospital diabetes clinic were included. Fifty patients were randomized to receive SGLT2 inhibitors in addition to baseline treatment (Group A), 47 subjects continued with their baseline treatment or were added other medications as needed (Group B). Thirty healthy controls (HC) were recruited (Group C). All groups were subjected to the Turkish version of Short Form-36 (SF-36), Pittsburgh Sleep Quality (PSQ), and Beck Anxiety Inventory (BAI) scales both at baseline and final visit. Results: Physical function, emotional role limitation, vitality, mental health, pain, general health perception scores of SF-36 were significantly improved in Group A, at the end of the follow-up period. There was no significant change in terms of PSQ, BAI scores, and hypoglycaemia documented in all groups. The intervention-related change in HbA1c level, body weight, and body mass index were significantly higher in Group A. Conclusion: The QoL was improved in people with diabetes who were taking SGLT2 inhibitors. This may be explained by weight loss observed in participants.Key words: Anxiety, sleep quality, quality of life, sodium-glucose co-transporter 2 inhibitor

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care 2015; 38 (1): 140-149. doi: 10.2337/dc14-2441
2. Salber GJ, Wang YB, Lynch JT, Pasquale KM, Rajan TV et al. Metformin use in practice: compliance with guidelines for patients with diabetes and preserved renal function. Clinical Diabetes 2017; 35 (3): 154-161. doi: 10.2337/cd15-0045
3. Dardi I, Kouvatsos T, Jabbour SA. SGLT2 inhibitors. Biochemical Pharmacology 2016; 101:27-39. doi: 10.1016/j.bcp.2015.09.005
4. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020; 41 (2):255-323. doi: 10.1093/eurheartj/ ehz486
5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. American Heart Journal 2018; 200: 83-89. doi: 10.1016/j.ahj.2018.01.012
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine 2015; 373 (22):2117-2128. doi: 10.1056/NEJMoa1504720
7. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Research and Clinical Practice 2014; 103 (3):373-381. doi: 10.1016/j. diabres.2013.12.052
8. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes/ Metabolism Research and Reviews1999;15(3):205-218. doi: 10.1002/(SICI)1520-7560(199905/06)15:3<205::AIDDMRR29>3.0.CO;2-O
9. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism 2011;13 (10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x
10. Nauck MA, Del Prato S, Meier JJ, Durán-GARCÍA S, Rohwedder K et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, doubleblind, active-controlled noninferiority trial. Diabetes Care 2011; 34 (9): 2015-2022. doi: 10.2337/dc11-0606
11. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. The Lancet 2010; 375 (9733): 2223-2233. doi: 10.1016/S0140-6736(10)60407-2
12. Farahani P. Lack of health-related quality of life and patientcentred outcome measures in randomized controlled trials conducted for diabetes pharmacotherapy: SGLT-2 receptor inhibitors as an example. Journal of Population Therapeutics and Clinical Pharmacology 2017; 24 (1): e1-e14. doi: 10.22374/1710-6222.24.1.2
13. Grandy S, Langkilde AM, Sugg JE, Parikh S, Sjöström CD. Healthrelated quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. International Journal of Clinical Practice 2014; 68 (4): 486-494. doi: 10.1111/ ijcp.12341
14. Grandy S, Langkilde AM, Ingelgard A, Sugg JE, Parikh S. Quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin for 24 weeks. Diabetes 2012; 61 (Supplement1): A600. doi: 10.2337/db12-2323-2568
15. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S et al. Hypoglycemia and diabetes: A report of a workgroup of the american diabetes association and the endocrine society. Journal of Clinical Endocrinology and Metabolism 2013; 98 (5):1845-1859. doi: 10.1210/jc.2012-4127
16. Ware E. SF-36 Health Survey update. Spine 2000; 25 (24): 3130- 3139. doi: 10.1097/00007632-200012150-00008
17. Koçyiğit H, Aydemir Ö, Fisek G, Ölmez N, Memiş A. Kısa Form36 (KF-36)’nın Türkçe versiyonunun güvenilirliği ve geçerliliği: romatizmal hastalığı olan bir grup hasta ile çalışma. İlaç ve Tedavi Dergisi 1999; 12 (2):102-106. (in Turkish).
18. Ağargün MY, Kara H, Anlar Ö. Pittsburgh uyku kalitesi indeksi’nin geçerliği ve güvenirliği. Türk Psikiyatri Dergisi 1996; 7 (2):107-115 (Article in Turkish).
19. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the beck anxiety inventory: psychometric properties. Journal of Cognitive Psychotherapy: An International Quarterly 1998; 12 (2): 163-172.
20. Luscombe FA. Health-related quality of life measurement in type 2 diabetes. Value in Health 2000; 3 (1): 15-28. doi: 10.1046/j.1524-4733.2000.36032.x
21. Grandy S, Chapman RH, Fox KM. Quality of life and depression of people living with type 2 diabetes mellitus and those at low and high risk for type 2 diabetes: findings from the study to help improve early evaluation and management of risk factors leading to diabetes (SHIELD). International Journal of Clinical Practice 2008; 62 (4): 562-568. doi: 10.1111/j.1742- 1241.2008.01703.x
22. Goddijn PPM, Bilo HJG, Feskens EJM, Groenier KH, Van der Zee KI et al. Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control. Diabetic Medicine 1999; 16 (1): 23-30. doi: 10.1046/j.1464-5491.1999.00002.x
23. Lau CY, Qureshi AK, Scott SG. Association between glycaemic control and quality of life in diabetes mellitus. Journal of Postgraduate Medicine 2004; 50 (3): 189-193.
24. Ishii H, Niiya T, Ono Y, Inaba N, Jinnouchi H et al. Improvement of quality of life through glycemic control by liraglutide, a GLP1 analog, in insulin-naive patients with type 2 diabetes mellitus: The PAGE1 study. Diabetology & Metabolic Syndrome 2017; 9: 3. doi: 10.1186/s13098-016-0202-0
25. Sridhar GR, Madhu K. Prevalence of sleep disturbances in diabetes mellitus. Diabetes Research and Clinical Practice 1994; 23 (3): 183-186. doi: 10.1016/0168-8227(94)90103-1
26. Luyster FS, Dunbar-Jacob J. Sleep quality and quality of life in adults with type 2 diabetes. Diabetes Educator 2011; 37 (3): 347-355. doi: 10.1177/0145721711400663
27. Sakamoto R, Yamakawa T, Takahashi K, Suzuki J, Shinoda MM et al. Association of usual sleep quality and glycemic control in type 2 diabetes in Japanese: A cross sectional study. Sleep and Food Registry in Kanagawa (SOREKA). PLoS ONE 2018; 13 (1): e0191771. doi: 10.1371/journal.pone.0191771
28. Knutson KL, Ryden AM, Mander BA, Cauter EV. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med 2006; 166 (16): 1768-74. doi: 10.1001/archinte.166.16.1768
29. Kara B, Kılıç Ö. Predictors of poor sleep quality and excessive daytime sleepiness in Turkish adults with type 2 diabetes. Journal of Clinical Nursing 2015; 24 (9-10): 1436-1439. doi: 10.1111/jocn.12710
30. Zhu B, Hershberger PE, Kapella MC, Fritschi C. The relationship between sleep disturbance and glycaemic control in adults with type 2 diabetes: an integrative review. Journal of Clinical Nursing 2017; 26 (23-24): 4053-4064. doi: 10.1111/jocn.13899
31. Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabetic Medicine 2009; 26 (2):153-161. doi: 10.1111/j.1464-5491.2008.02648.x
32. Masmoudi J, Damak R, Zouari H, Ouali U, Mechri A et al. Prevalence and impact of anxiety and depression on type 2 diabetes in tunisian patients over sixty years old. Depression Research and Treatment 2013; 2013:341782. doi: 10.1155/2013/341782
33. Khuwaja AK, Lalani S, Dhanani R, Azam IS, Rafique G et al. Anxiety and depression among outpatients with type 2 diabetes: A multi-centre study of prevalence and associated factors. Diabetology and Metabolic Syndrome 2010; 2: 72. doi: 10.1186/1758-5996-2-72
34. Grandy S, Fox KM, Bazata DD. Association of self-reported weight change and quality of life, and exercise and weight management behaviors among adults with type 2 diabetes mellitus: The SHIELD study. Cardiology Research and Practice 2012; 2012: 892564. doi: 10.1155/2012/892564
35. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes, Obesity and Metabolism 2014; 16 (7): 645-650. doi: 10.1111/ dom.12263
36. Traina S, Guthrie R, Slee A. The impact of weight loss on weightrelated quality of life and health satisfaction: Results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgraduate Medicine 2014; 126 (3): 7-15. doi: 10.3810/pgm.2014.05.2752
37. Asplund R. Nocturia in relation to sleep, health, and medical treatment in the elderly. BJU International 2005; 96: 15-21. doi: 10.1111/j.1464-410X.2005.05653.x
38. Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU International 2003; 92 (9): 948-954. doi: 10.1111/j.1464- 410X.2003.04527.x
39. Sheu WHH, Ji LN, Nitiyanant W, Baik SH, Yin D et al. Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region. Diabetes Research and Clinical Practice 2012; 96 (2): 141-148. doi: 10.1016/j.diabres.2011.12.027
40. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Research Notes 2011 21; 4: 251. doi: 10.1186/1756-0500-4-251
41. Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgraduate Medicine 2018; 130 (1): 72-82. doi: 10.1080/00325481.2018.1394152
42. Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB et al. Benefits and harms of Sodium-Glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 2016; 11 (11): e0166125. doi: 10.1371/journal.pone.0166125
43. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Annals of Internal Medicine 2013; 159 (4): 262-274. doi: 10.7326/0003- 4819-159-4-201308200-00007
44. Liu J, Li L, Li S, Jia P, Deng K et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Scientific Reports 2017; 7 (1): 2824. doi: 10.1038/s41598-017-02733-w
45. Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. Journal of Clinical Hypertension 2014; 16 (12): 875-882. doi: 10.1111/jch.12425
46. Chen LH, Leung PS. Inhibition of the sodium glucose cotransporter-2: Its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2013; 15 (5): 392-402. doi: 10.1111/dom.12064

APA	Sahin S, Haliloglu O, Polat Korkmaz O, DURCAN E, Rekalı Sahin H, Yumuk V, Damci T, Ilkova H, Osar Siva Z (2021). Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. , 735 - 742. 10.3906/sag-2008-37
Chicago	Sahin Serdar,Haliloglu Ozlem,Polat Korkmaz Ozge,DURCAN EMRE,Rekalı Sahin Humeyra,Yumuk Volkan Demirhan,Damci Taner,Ilkova Hasan,Osar Siva Zeynep Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. (2021): 735 - 742. 10.3906/sag-2008-37
MLA	Sahin Serdar,Haliloglu Ozlem,Polat Korkmaz Ozge,DURCAN EMRE,Rekalı Sahin Humeyra,Yumuk Volkan Demirhan,Damci Taner,Ilkova Hasan,Osar Siva Zeynep Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. , 2021, ss.735 - 742. 10.3906/sag-2008-37
AMA	Sahin S,Haliloglu O,Polat Korkmaz O,DURCAN E,Rekalı Sahin H,Yumuk V,Damci T,Ilkova H,Osar Siva Z Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. . 2021; 735 - 742. 10.3906/sag-2008-37
Vancouver	Sahin S,Haliloglu O,Polat Korkmaz O,DURCAN E,Rekalı Sahin H,Yumuk V,Damci T,Ilkova H,Osar Siva Z Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. . 2021; 735 - 742. 10.3906/sag-2008-37
IEEE	Sahin S,Haliloglu O,Polat Korkmaz O,DURCAN E,Rekalı Sahin H,Yumuk V,Damci T,Ilkova H,Osar Siva Z "Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?." , ss.735 - 742, 2021. 10.3906/sag-2008-37
ISNAD	Sahin, Serdar vd. "Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?". (2021), 735-742. https://doi.org/10.3906/sag-2008-37

APA	Sahin S, Haliloglu O, Polat Korkmaz O, DURCAN E, Rekalı Sahin H, Yumuk V, Damci T, Ilkova H, Osar Siva Z (2021). Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. Turkish Journal of Medical Sciences, 51(2), 735 - 742. 10.3906/sag-2008-37
Chicago	Sahin Serdar,Haliloglu Ozlem,Polat Korkmaz Ozge,DURCAN EMRE,Rekalı Sahin Humeyra,Yumuk Volkan Demirhan,Damci Taner,Ilkova Hasan,Osar Siva Zeynep Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. Turkish Journal of Medical Sciences 51, no.2 (2021): 735 - 742. 10.3906/sag-2008-37
MLA	Sahin Serdar,Haliloglu Ozlem,Polat Korkmaz Ozge,DURCAN EMRE,Rekalı Sahin Humeyra,Yumuk Volkan Demirhan,Damci Taner,Ilkova Hasan,Osar Siva Zeynep Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. Turkish Journal of Medical Sciences, vol.51, no.2, 2021, ss.735 - 742. 10.3906/sag-2008-37
AMA	Sahin S,Haliloglu O,Polat Korkmaz O,DURCAN E,Rekalı Sahin H,Yumuk V,Damci T,Ilkova H,Osar Siva Z Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. Turkish Journal of Medical Sciences. 2021; 51(2): 735 - 742. 10.3906/sag-2008-37
Vancouver	Sahin S,Haliloglu O,Polat Korkmaz O,DURCAN E,Rekalı Sahin H,Yumuk V,Damci T,Ilkova H,Osar Siva Z Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?. Turkish Journal of Medical Sciences. 2021; 51(2): 735 - 742. 10.3906/sag-2008-37
IEEE	Sahin S,Haliloglu O,Polat Korkmaz O,DURCAN E,Rekalı Sahin H,Yumuk V,Damci T,Ilkova H,Osar Siva Z "Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?." Turkish Journal of Medical Sciences, 51, ss.735 - 742, 2021. 10.3906/sag-2008-37
ISNAD	Sahin, Serdar vd. "Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?". Turkish Journal of Medical Sciences 51/2 (2021), 735-742. https://doi.org/10.3906/sag-2008-37